MHRA approval of dostarlimab (Jemperli) for recurrent or advanced endometrial cancer

Dostarlimab is the first anti-PD-1 therapy approved as monotherapy for use in adults with mismatch repair deficient or microsatellite instability-high recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen.

Source:

PharmaTimes